Mattea Reinisch
GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer.
Möbus V, Lück H, Ladda E, Klare P, Engels K, Schmidt M, Schneeweiss A, Grischke E, Wachsmann G, Forstbauer H, Untch M, Marme F, Blohmer J, Jackisch C, Huober J, Stickeler E, Reinisch M, Link T, Sinn B, Janni W, Denkert C, Seiler S, Solbach C, Schmatloch S, Rey J, Loibl S. GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer. NPJ Breast Cancer 2024; 10:66.
Jul 30, 2024GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer.
Jul 30, 2024NPJ Breast Cancer 2024; 10:66
Möbus Volker, Lück Hans-Joachim, Ladda Ekkehart, Klare Peter, Engels Knut, Schmidt Marcus, Schneeweiss Andreas, Grischke Eva-Maria, Wachsmann Grischa, Forstbauer Helmut, Untch Michael, Marme Frederik, Blohmer Jens-Uwe, Jackisch Christian, Huober Jens, Stickeler Elmar, Reinisch Mattea, Link Theresa, Sinn Bruno Valentin, Janni Wolfgang, Denkert Carsten, Seiler Sabine, Solbach Christine, Schmatloch Sabine, Rey Julia, Loibl Sibylle
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Meyer-Wilmes P, Huober J, Untch M, Blohmer J, Janni W, Denkert C, Klare P, Link T, Rhiem K, Bayer C, Reinisch M, Bjelic-Radisic V, Zahm D, Hanusch C, Solbach C, Heinrich G, Hartkopf A, Schneeweiss A, Fasching P, Filmann N, Nekljudova V, Holtschmidt J, Stickeler E, Loibl S. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). ESMO Open 2024; 9:103009.
Apr 24, 2024Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Apr 24, 2024ESMO Open 2024; 9:103009
Meyer-Wilmes P, Huober Jens, Untch Michael, Blohmer J-U, Janni Wolfgang, Denkert Carsten, Klare Peter, Link Theresa, Rhiem Kerstin, Bayer C, Reinisch Mattea, Bjelic-Radisic Vesna, Zahm Dirk Michael, Hanusch Claus, Solbach Christine, Heinrich Georg, Hartkopf Andreas D, Schneeweiss Andreas, Fasching Peter Andreas, Filmann N, Nekljudova Valentina, Holtschmidt J, Stickeler Elmar, Loibl Sibylle
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
Fasching P, Decker T, Hartkopf A, Nusch A, Heinrich B, Kurbacher C, Fuchs R, Tesch H, Krabisch P, Huober J, Kümmel S, Brucker S, Janni W, Schneeweiss A, Schuler M, Fehm T, Luftner D, Quiering C, Voges C, Kreuzeder J, Reinisch M. Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer. Eur J Cancer 2023; 198:113480.
Dec 15, 2023Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
Dec 15, 2023Eur J Cancer 2023; 198:113480
Fasching Peter Andreas, Decker Thomas, Hartkopf Andreas D, Nusch Arnd, Heinrich Bernhard J, Kurbacher Christian M, Fuchs Roswitha, Tesch Hans, Krabisch Petra, Huober Jens, Kümmel Sherko, Brucker Sara Y, Janni Wolfgang, Schneeweiss Andreas, Schuler Martin, Fehm Tanja N, Luftner Diana, Quiering Claudia, Voges Claudia, Kreuzeder Julia, Reinisch Mattea
ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment-A New Concept.
Pfob A, Cai L, Schneeweiss A, Rauch G, Thomas B, Schaefgen B, Kümmel S, Reimer T, Hahn M, Thill M, Blohmer J, Hackmann J, Malter W, Bekes I, Friedrichs K, Wojcinski S, Joos S, Paepke S, Degenhardt T, Rom J, Rody A, van Mackelenbergh M, Banys-Paluchowski M, Große R, Reinisch M, Karsten M, Sidey-Gibbons C, Wallwiener M, Golatta M, Heil J. ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment-A New Concept. Ann Surg Oncol 2023
Dec 13, 2023ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment-A New Concept.
Dec 13, 2023Ann Surg Oncol 2023
Pfob André, Cai Lie, Schneeweiss Andreas, Rauch Geraldine, Thomas Bettina, Schaefgen Benedikt, Kümmel Sherko, Reimer Toralf, Hahn Markus, Thill Marc, Blohmer Jens-Uwe, Hackmann John, Malter Wolfram, Bekes Inga, Friedrichs Kay, Wojcinski Sebastian, Joos Sylvie, Paepke Stefan, Degenhardt Tom, Rom Joachim, Rody Achim, van Mackelenbergh Marion T, Banys-Paluchowski Maggie, Große Regina, Reinisch Mattea, Karsten Maria Margarete, Sidey-Gibbons Chris, Wallwiener Markus, Golatta Michael, Heil Jörg
Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept.
Pfob A, Cai L, Schneeweiss A, Rauch G, Thomas B, Schaefgen B, Kümmel S, Reimer T, Hahn M, Thill M, Blohmer J, Hackmann J, Malter W, Bekes I, Friedrichs K, Wojcinski S, Joos S, Paepke S, Degenhardt T, Rom J, Rody A, van Mackelenbergh M, Banys-Paluchowski M, Große R, Reinisch M, Karsten M, Sidey-Gibbons C, Wallwiener M, Golatta M, Heil J. Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept. Ann Surg Oncol 2023
Nov 10, 2023Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept.
Nov 10, 2023Ann Surg Oncol 2023
Pfob André, Cai Lie, Schneeweiss Andreas, Rauch Geraldine, Thomas Bettina, Schaefgen Benedikt, Kümmel Sherko, Reimer Toralf, Hahn Markus, Thill Marc, Blohmer Jens-Uwe, Hackmann John, Malter Wolfram, Bekes Inga, Friedrichs Kay, Wojcinski Sebastian, Joos Sylvie, Paepke Stefan, Degenhardt Tom, Rom Joachim, Rody Achim, van Mackelenbergh Marion T, Banys-Paluchowski Maggie, Große Regina, Reinisch Mattea, Karsten Maria Margarete, Sidey-Gibbons Chris, Wallwiener Markus, Golatta Michael, Heil Jörg
RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial.
Link T, Blohmer J, Schmitt W, Kuhlmann J, Just M, Untch M, Stötzer O, Fasching P, Thill M, Reinisch M, Schneeweiss A, Wimberger P, Seiler S, Huober J, Jackisch C, Rhiem K, Hanusch C, Sinn B, Nekljudova V, Loibl S, Denkert C. RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial. Clin Cancer Res 2023
Sep 19, 2023RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial.
Sep 19, 2023Clin Cancer Res 2023
Link Theresa, Blohmer Jens-Uwe, Schmitt Wolfgang Daniel, Kuhlmann Jan Dominik, Just Marianne, Untch Michael, Stötzer Oliver, Fasching Peter Andreas, Thill Marc, Reinisch Mattea, Schneeweiss Andreas, Wimberger Pauline, Seiler Sabine, Huober Jens, Jackisch Christian, Rhiem Kerstin, Hanusch Claus, Sinn Bruno Valentin, Nekljudova Valentina, Loibl Sibylle, Denkert Carsten
Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy.
Huober J, van Mackelenbergh M, Schneeweiss A, Seither F, Blohmer J, Denkert C, Tesch H, Hanusch C, Salat C, Rhiem K, Solbach C, Fasching P, Jackisch C, Reinisch M, Lederer B, Mehta K, Link T, Nekljudova V, Loibl S, Untch M. Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy. NPJ Breast Cancer 2023; 9:23.
Apr 7, 2023Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy.
Apr 7, 2023NPJ Breast Cancer 2023; 9:23
Huober Jens, van Mackelenbergh Marion T, Schneeweiss Andreas, Seither Fenja, Blohmer Jens-Uwe, Denkert Carsten, Tesch Hans, Hanusch Claus, Salat Christoph, Rhiem Kerstin, Solbach Christine, Fasching Peter Andreas, Jackisch Christian, Reinisch Mattea, Lederer Bianca, Mehta Keyur M, Link Theresa, Nekljudova Valentina, Loibl Sibylle, Untch Michael
Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery
Pfob A, Joos S, Paepke S, Degenhardt T, Rom J, Rody A, van Mackelenbergh M, Banys-Paluchowski M, Große R, Reinisch M, Karsten M, Golatta M, Wojcinski S, Friedrichs K, Bekes I, Sidey-Gibbons C, Rauch G, Thomas B, Schaefgen B, Kuemmel S, Reimer T, Hahn M, Thill M, Blohmer J, Hackmann J, Malter W, Heil J. Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery. J Clin Oncol 2022:JCO2102439.
Feb 2, 2022Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery
Feb 2, 2022J Clin Oncol 2022:JCO2102439
Pfob André, Joos Sylvie, Paepke Stefan, Degenhardt Tom, Rom Joachim, Rody Achim, van Mackelenbergh Marion, Banys-Paluchowski Maggie, Große Regina, Reinisch Mattea, Karsten Maria, Golatta Michael, Wojcinski Sebastian, Friedrichs Kay, Bekes Inga, Sidey-Gibbons Chris, Rauch Geraldine, Thomas Bettina, Schaefgen Benedikt, Kuemmel Sherko, Reimer Toralf, Hahn Markus, Thill Marc, Blohmer Jens-Uwe, Hackmann John, Malter Wolfram, Heil Joerg
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
Blohmer J, Jackisch C, Rhiem K, Solbach C, Hanusch C, Seither F, Denkert C, Engels K, Nekljudova V, Loibl S, Thill M, Huober J, Link T, Reinisch M, Just M, Untch M, Stötzer O, Fasching P, Schneeweiss A, Wimberger P, Seiler S, GBG and AGO-B. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. JAMA Oncol 2022; 8:1010-1018.
Jan 1, 2022Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
Jan 1, 2022JAMA Oncol 2022; 8:1010-1018
Blohmer Jens-Uwe, Jackisch Christian, Rhiem Kerstin, Solbach Christine, Hanusch Claus, Seither Fenja, Denkert Carsten, Engels Knut, Nekljudova Valentina, Loibl Sibylle, Thill Marc, Huober Jens, Link Theresa, Reinisch Mattea, Just Marianne, Untch Michael, Stötzer Oliver, Fasching Peter A, Schneeweiss Andreas, Wimberger Pauline, Seiler Sabine, GBG and AGO-B
Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
Knauer M, Winkler J, Reinisch M, Reitsamer R, Singer C, Reisenberger K, Hager C, Fansa H, Exner R, Dubsky P, Berclaz G, Leo C, Lam G, Fehr M, Naydina T, Heil J, Egle D, Lelièvre L, Markellou P, Schulz A, Maggi N, Nussbaumer R, Fitzal F, Ostapenko V, Clerc K, Kohlik M, Dedes K, Sarlos D, Muenst S, Ruhstaller T, Maddox C, Seiler S, Zimmermann F, Gruber G, Zwahlen D, Henke G, Tausch C, Hayoz S, Matrai Z, Ackerknecht M, Kuemmel S, Bjelic-Radisic V, Maráz R, Gabriel N, Fehr P, Simonson C, Bucher S, Becciolini C, Meyer I, Satler R, Vrieling C, Újhelyi M, Kurzeder C, Weber W. Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). Breast 2021; 60:98-110.
Sep 8, 2021Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
Sep 8, 2021Breast 2021; 60:98-110
Knauer Michael, Winkler Jelena, Reinisch Mattea, Reitsamer Roland, Singer Christian F, Reisenberger Klaus, Hager Christopher, Fansa Hisham, Exner Ruth, Dubsky Peter, Berclaz Gilles, Leo Cornelia, Lam Giang Thanh, Fehr Mathias K, Naydina Tatiana, Heil Jörg, Egle Daniel, Lelièvre Loic, Markellou Pagona, Schulz Alexandra, Maggi Nadia, Nussbaumer Rahel, Fitzal Florian, Ostapenko Valerijus, Clerc Karine, Kohlik Magdalena, Dedes Konstantin J, Sarlos Dimitri, Muenst Simone, Ruhstaller Thomas, Maddox Charlotte, Seiler Stefanie, Zimmermann Frank, Gruber Günther, Zwahlen Daniel R, Henke Guido, Tausch Christoph, Hayoz Stefanie, Matrai Zoltan, Ackerknecht Markus, Kuemmel Sherko, Bjelic-Radisic Vesna, Maráz Robert, Gabriel Natalie, Fehr Peter M, Simonson Colin, Bucher Susanne, Becciolini Charles, Meyer Inna, Satler Rok, Vrieling Conny, Újhelyi Mihály, Kurzeder Christian, Weber Walter P
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)
Möbus V, Reinisch M, Link T, Sinn B, Janni W, Denkert C, Furlanetto J, Engels K, Solbach C, Schmatloch S, Rey J, Burchardi N, Loibl S, Stickeler E, Huober J, Lück H, Ladda E, Klare P, Schmidt M, Schneeweiss A, Grischke E, Wachsmann G, Forstbauer H, Untch M, Marme F, Blohmer J, Jackisch C, GBG and AGO-B. Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). Eur J Cancer 2021; 156:138-148.
Aug 24, 2021Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)
Aug 24, 2021Eur J Cancer 2021; 156:138-148
Möbus Volker, Reinisch Mattea, Link Theresa, Sinn Bruno V, Janni Wolfgang, Denkert Carsten, Furlanetto Jenny, Engels Knut, Solbach Christine, Schmatloch Sabine, Rey Julia, Burchardi Nicole, Loibl Sibylle, Stickeler Elmar, Huober Jens, Lück Hans-Joachim, Ladda Ekkehart, Klare Peter, Schmidt Marcus, Schneeweiss Andreas, Grischke Eva-Maria, Wachsmann Grischa, Forstbauer Helmut, Untch Michael, Marme Frederik, Blohmer Jens-Uwe, Jackisch Christian, GBG and AGO-B
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
Denkert C, Huober J, Rhiem K, Marme F, Reimer T, Schmidt M, Sinn B, Janni W, Stickeler E, Michel L, Stötzer O, Hahnen E, Furlanetto J, Seiler S, Nekljudova V, Untch M, Solbach C, Lübbe K, Seither F, Schneeweiss A, Link T, Blohmer J, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, Schmatloch S, Reinisch M, Solomayer E, Schmitt W, Hanusch C, Fasching P, Loibl S. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol 2021; 22:1151-1161.
Jul 9, 2021Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
Jul 9, 2021Lancet Oncol 2021; 22:1151-1161
Denkert Carsten, Huober Jens, Rhiem Kerstin, Marme Frederik, Reimer Toralf, Schmidt Marcus, Sinn Bruno V, Janni Wolfgang, Stickeler Elmar, Michel Laura, Stötzer Oliver, Hahnen Eric, Furlanetto Jenny, Seiler Sabine, Nekljudova Valentina, Untch Michael, Solbach Christine, Lübbe Kristina, Seither Fenja, Schneeweiss Andreas, Link Theresa, Blohmer Jens-Uwe, Just Marianne, Wimberger Pauline, Forberger Almuth, Tesch Hans, Jackisch Christian, Schmatloch Sabine, Reinisch Mattea, Solomayer Erich F, Schmitt Wolfgang D, Hanusch Claus, Fasching Peter A, Loibl Sibylle
Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03
Heil J, Friedrichs K, Wojcinski S, Joos S, Paepke S, Ditsch N, Rody A, Große R, van Mackelenbergh M, Reinisch M, Karsten M, Golatta M, Bekes I, Malter W, Hackmann J, Pfob A, Sinn H, Rauch G, Bach P, Thomas B, Schaefgen B, Kuemmel S, Reimer T, Hahn M, Thill M, Blohmer J, RESPONDER Investigators. Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03. Ann Surg 2020
Jul 9, 2020Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03
Jul 9, 2020Ann Surg 2020
Heil Joerg, Friedrichs Kay, Wojcinski Sebastian, Joos Sylvie, Paepke Stefan, Ditsch Nina, Rody Achim, Große Regina, van Mackelenbergh Marion, Reinisch Mattea, Karsten Maria, Golatta Michael, Bekes Inga, Malter Wolfram, Hackmann John, Pfob André, Sinn Hans-Peter, Rauch Geraldine, Bach Paul, Thomas Bettina, Schaefgen Benedikt, Kuemmel Sherko, Reimer Toralf, Hahn Markus, Thill Marc, Blohmer Jens-Uwe, RESPONDER Investigators
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
Laakmann E, Ingold-Heppner B, Huober J, Hanusch C, Jackisch C, Reinisch M, Untch M, von Minckwitz G, Nekljudova V, Müller V, Blohmer J, Zahm D, Witzel I, Fasching P, Rezai M, Schem C, Solbach C, Tesch H, Klare P, Schneeweiss A, Salat C, Loibl S. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. Breast Cancer Res 2019; 21:60.
May 10, 2019Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
May 10, 2019Breast Cancer Res 2019; 21:60
Laakmann Elena, Ingold-Heppner Barbara, Huober Jens, Hanusch Claus, Jackisch Christian, Reinisch Mattea, Untch Michael, von Minckwitz Gunter, Nekljudova Valentina, Müller Volkmar, Blohmer Jens-Uwe, Zahm Dirk-Michael, Witzel Isabell, Fasching Peter A, Rezai Mahdi, Schem Christian, Solbach Christine, Tesch Hans, Klare Peter, Schneeweiss Andreas, Salat Christoph, Loibl Sibylle
pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials
Reinisch M, Nekljudova V V, Untch M, Lederer B, Rhiem K, Schneeweiss A, Kümmel S, Jackisch C, Hanusch C, Denkert C, Blohmer J, von Minckwitz G, Huober J, Loibl S. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. Breast 2017; 32:73-78.
Jan 5, 2017pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials
Jan 5, 2017Breast 2017; 32:73-78
Reinisch Mattea, Nekljudova V Valentina, Untch Michael, Lederer Bianca, Rhiem Kerstin, Schneeweiss Andreas, Kümmel Sherko, Jackisch Christian, Hanusch Claus, Denkert Carsten, Blohmer Jens-Uwe, von Minckwitz Gunter, Huober Jens, Loibl Sibylle
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
Denkert C, von Minckwitz G, Tesch H, Hansmann M, Reinisch M, Engels K, Sinn B, Fasching P, Mehta K, Solbach C, Brase J, Darb-Esfahani S, Kronenwett R, Prinzler J, Loibl S, Huober J, Untch M. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res 2013; 15:R11.
Feb 7, 2013HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
Feb 7, 2013Breast Cancer Res 2013; 15:R11
Denkert Carsten, von Minckwitz Gunter, Tesch Hans, Hansmann Martin-Leo, Reinisch Mattea, Engels Knut, Sinn Bruno V, Fasching Peter A, Mehta Keyur, Solbach Christine, Brase Jan C, Darb-Esfahani Silvia, Kronenwett Ralf, Prinzler Judith, Loibl Sibylle, Huober Jens, Untch Michael